Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2006 1
2008 2
2011 3
2015 1
2016 1
2017 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Fisher JG, et al. Among authors: veljovich d. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7. Target Oncol. 2020. PMID: 33090333
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Holmberg LA, Goff B, Veljovich D. Holmberg LA, et al. Among authors: veljovich d. Gynecol Oncol. 2011 May 1;121(2):426. doi: 10.1016/j.ygyno.2010.11.049. Epub 2011 Feb 15. Gynecol Oncol. 2011. PMID: 21324515 Clinical Trial. No abstract available.
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Goff BA, Holmberg LA, Veljovich D, Kurland BF; Puget Sound Oncology Consortium. Goff BA, et al. Among authors: veljovich d. Gynecol Oncol. 2008 Aug;110(2):146-51. doi: 10.1016/j.ygyno.2008.04.037. Epub 2008 Jun 6. Gynecol Oncol. 2008. PMID: 18538834 Clinical Trial.